# EDGAR Filing Document

**Accession Number:** 0000925741
**File Stem:** 0001437749-25-036711
**Filing Date:** 2025-12
**Character Count:** 15656
**Document Hash:** 51e9590cb2a52019179a0919aa84ddae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-036711.hdr.sgml**: 20251203

**ACCESSION NUMBER**: 0001437749-25-036711

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251202

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251203

**DATE AS OF CHANGE**: 20251203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioCardia, Inc.
- **CENTRAL INDEX KEY:** 0000925741
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 232753988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38999
- **FILM NUMBER:** 251545019

**BUSINESS ADDRESS:**
- **STREET 1:** 320 SOQUEL WAY
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085
- **BUSINESS PHONE:** 650-226-0123

**MAIL ADDRESS:**
- **STREET 1:** 320 SOQUEL WAY
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tiger X Medical, Inc.
- **DATE OF NAME CHANGE:** 20110616

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cardo Medical, Inc.
- **DATE OF NAME CHANGE:** 20081027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CLICKNSETTLE COM INC
- **DATE OF NAME CHANGE:** 20000823

?xml version='1.0' encoding='ASCII'? bcda20251202_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 2, 2025**

---

| |
|:---|
| **BIOCARDIA, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38999** | **23-2753988** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| |
|:---|
| **320 Soquel Way** <br> **Sunnyvale, California 94085** |
| (Address of principal executive offices and zip code) |

---

**Registrant**'**s telephone number, including area code: (650) 226-0120**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which<br> registered |
| Common Stock, par value $0.001<br> BCDA | The Nasdaq Capital Market |

---

---

| |
|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

------

**Item 5.02**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 2, 2025, the Board of Directors (the "Board") of BioCardia, Inc. (the "Company" or "BioCardia") appointed Marvin Slosman as a member of the Board, with an initial term beginning immediately and expiring at BioCardia's 2028 Annual Meeting of Shareholders, or until his successor is duly elected and qualified. Mr. Slosman is President, Chief Executive Officer and a director of InspireMD, Inc., a NASDAQ listed medical device company focused on vascular and carotid artery disease management solutions. He has served in that capacity since January 2020.

The Board has determined that Mr. Slosman qualifies as an independent director under the corporate governance standards of Nasdaq, and there are no arrangements or understandings between Mr. Slosman and any other persons pursuant to which Mr. Slosman was selected as a director. The Board has appointed Mr. Slosman to serve on the Company's Audit Committee. The Company is not aware of any transaction involving Mr. Slosman requiring disclosure under Item 404(a) of Regulation S-K.

As compensation for his service on the Board, Mr. Slosman will receive cash and equity compensation provided by the Company's Non-Employee Director Compensation Policy, as it may be adjusted by the Board from time to time as described in the Company's 2025 Proxy Statement.

In addition, the Company and Mr. Slosman will enter into the Company's standard form of indemnification agreement for directors.

Dr. Richard Krasno, who has served on the Company's board of directors since 2016, completed his term on the board of directors on December 2, 2025. Dr. Krasno's departure was not because of any disagreement with the Company on any matter relating to its operations, policies or practices.

**Item 5.07**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Submission of Matters to a Vote of Security Holders.**

On December 2, 2025, the Company held its Annual Meeting. Present at the Annual Meeting in person or by proxy were holders of 5,913,667 shares of the Company's common stock, representing 55.72% of the voting power of the shares of the Company's common stock as of October 8, 2025, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. The matters before the Annual Meeting are described in more detail in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on November 3, 2025.

*Proposal 1* – *Election of Directors*. The following nominees were elected as Class III directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Withheld** | **Broker Non-votes** |
| Marvin Slosman | 3,550,719 | 198,084 | 2,164,864 |
| Jay M. Moyes | 3,550,555 | 198,248 | 2,164,864 |
| Simon H. Stertzer, M.D. | 3,557,464 | 191,339 | 2,164,864 |

---

*Proposal 2* – *Approval of an amendment, restatement and extension to our 2016 Equity Incentive Plan.* The amendment to (i) extend the term of the Restated Plan until October 31, 2035, (ii) change the automatic share reserve increase pursuant to the Restated Plan to automatically increase the number of shares available for issuance under the Restated Plan on the date of this Annual Meeting and the first day of each fiscal year following this Annual Meeting, in an amount equal to, subject to the limitations in the 2016 Plan, four percent (4.0%) of the outstanding shares on the day immediately preceding each automatic increase, and (iii) limit the portion of the share reserve available for issuance pursuant to the exercise of incentive stock options, was approved.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-votes** |
| 2,654,280 | 478,152 | 616,371 | 2,164,864 |

---

------

*Proposal 3* – *Ratification of the Appointment of Independent Registered Public Accounting Firm.* The appointment of PKF San Diego, LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025, was ratified.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-votes** |
| 5,675,396 | 66,239 | 172,032 | --- |

---

*Proposal 4* – *Approval, on an Advisory Basis, of the Company*'*s Executive Compensation*. The Company's executive compensation was approved on an advisory basis.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-votes** |
| 2,863,009 | 107,183 | 778,611 | 2,164,864 |

---

**Item 7.01**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Regulation FD Disclosure.**

On December 2, 2025, the BioCardia issued a press release announcing the appointment of Marvin Slosman to its board of directors and the completion of Dr. Richard Krasno's term on the board of directors, a copy of which is furnished as exhibit 99.1 to the Current Report of Form 8-K and is incorporated by reference herein.

The information furnished to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any registration statement of filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified in such filing as being incorporated by reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [<u>99.1</u>](ex_894853.htm) | [<u>BioCardia, Inc. press release dated December 3, 2025</u>](ex_894853.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| **BIOCARDIA, INC.** |
| /s/ Peter Altman, Ph.D. |
| Peter Altman, Ph.D. |
| President and Chief Executive Officer |
| Date: December 3, 2025 |

---

## Exhibit 99.1

**Exhibit 99.1**

**BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno**

**Sunnyvale, California** – **December 3, 2025 - BioCardia, Inc. [NASDAQ: BCDA]**, a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025.

"We are very pleased to welcome Mr. Slosman to our Board," said Peter Altman, Chief Executive Officer of BioCardia. "With deep expertise in the interventional cardiology sector and a strong track record in advancing breakthrough technologies from concept to commercialization, Mr. Slosman brings an exceptional understanding of regulatory pathways, global market expansion, and clinical value creation. He will be a tremendous asset as we continue to scale our portfolio and deliver innovative solutions for patients and providers."

Mr. Slosman currently serves as President, Chief Executive Officer, and Director of InspireMD, a NASDAQ listed medical device company focused on vascular and carotid-artery disease management solutions. In addition to experience as Chief Executive Officer, he has held positions as Chief Operating Officer, and senior commercial-leadership roles at major medical and healthcare companies, including Johnson & Johnson, GE Healthcare, and Baxter International Inc., helping drive commercialization and market development efforts. His background includes significant accomplishments in both public and private growth companies with expertise in regulatory pathways and approvals, strategic partnerships, product development, and operational and commercial growth in global technology markets.

CEO Altman also extended the Company's gratitude to Dr. Richard Krasno for his years of service. "Dr. Krasno has been a dedicated and highly respected member of our Board," said Mr. Altman. "During his tenure, he was instrumental in guiding the Company through key milestones, including clinical evidence development for the CardiAMP cell therapy for the treatment of ischemic heart failure, the Morph DNA product FDA approval, and expansion into new therapeutic areas of chronic myocardial ischemia acute myocardial infarction and pulmonary disease. We are deeply appreciative of his leadership and commitment to improving patient care."

Dr. Krasno served on several Board committees, including the Audit Committee and the Compensation Committee, and contributed extensively to strengthening governance, and supporting long-term strategic planning for our development efforts.

The Board and executive leadership team welcome the expertise of Mr. Slosman and express sincere thanks to Dr. Krasno for his significant contributions to the Company's mission of advancing therapies to treat cardiovascular disease.

------

**About BioCardia**®

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company's biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: <u>https://www.BioCardia.com</u>.

**Forward Looking Statements**

This press release contains forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia's Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled "Risk Factors," and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

###

**Media Contact:** <br> Miranda Peto, Investor Relations<br> Email: <u>mpeto@BioCardia.com</u><br> Phone: 650-226-0120

**Investor Contact:** <br> David McClung, Chief Financial Officer<br> Email: <u>investors@BioCardia.com</u><br> Phone: 650-226-0120